drugset / Trial / NCT01197794

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794

Phase 2 Completed 1144 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.

Timeline

Start
2010-10
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1981 Small molecule 10 mg
Subject AZD1981 Small molecule 40 mg
Subject AZD1981 Small molecule 80 mg
Subject AZD1981 Small molecule 100 mg
Subject AZD1981 Small molecule 200 mg
Subject AZD1981 Small molecule 400 mg

Indications